novo nordisk news - Search News

Novo Nordisk Stock Rises

Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'

Key Takeaways Novo Nordisk shares rose Wednesday on the company's home market in Denmark and in the U.S. after UBS analysts upgraded the stock.The analysts upgraded the Ozempic obesity drugmaker to a "buy,

Business Insider · 1d

Novo Nordisk upgraded to Buy from Neutral at UBS, as CagriSema selloff overdone

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed”

Fintel on MSN · 14h

UBS Upgrades Novo Nordisk A (NVO)

Fintel reports that on January 8, 2025, UBS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Sell to Buy. Analyst Price Forecast Suggests 61.15% Upside As of December 23, 2024, the average one-year price target for Novo Nordisk A is $137.

Novo Nordisk Expands AI Partnership With Valo Health

Reuters · 22h

Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and artificial intelligence (AI).

FierceBiotech · 1d

Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and billions on the back end—to apply artificial intelligence to up to 20 programs.

DPA International on MSN · 23h

Novo Nordisk expands drug collaboration with Valo Health

Denmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop novel treatments for obesity, type-2 diabetes, and cardiovascular disease. It has committed to a near-term payment of $190 million and the collaboration expects milestone payments of approximately $4.

Novo, Eli Lilly to dominate global pharma sales in 2025: report

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

23hon MSN

5 Questions Novo Nordisk Needs to Answer to Get Its Stock Moving Higher

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

Novo Nordisk Needs Answers to These 5 Key Questions

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

24/7 Wall St19h

Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

Becker's Hospital Review22h

Novo Nordisk joins Eli Lilly in legal challenge over GLP-1 compounding

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

20hon MSN

This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the most valuable healthcare stocks in the world, largely due ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Novo Nordisk Stock Rises

Novo Nordisk Expands AI Partnership With Valo Health

Related topics